Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer

Breast Cancer Research

Volumn 15, Issue 1, 2013, Pages

  Hunt, Kelly K ^a   Wingate, Hannah ^a   Yokota, Tomoya ^b   Liu, Yanna ^a   Mills, Gordon B ^a   Zhang, Fan ^a   Fang, Bingliang ^a   Su, Chun Hui ^a   Zhang, Ming ^c   Yi, Min ^a   Keyomarsi, Khandan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHIZUOKA CANCER CENTER   (Japan)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ELAFIN; ELASTASE; SHORT HAIRPIN RNA; PANCREATIC ELASTASE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA CELL; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST TUMOR; DRUG SCREENING; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; PROMOTER REGION; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; ELAFIN; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PANCREATIC ELASTASE; PROGNOSIS; PROMOTER REGIONS, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872150361     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3374     Document Type: Article

References (36)

1. Barrett AJ. Leukocyte elastase. Methods Enzymol 1981, 80:581-588.
2. Yamashita JI, Ogawa M, Ikei S, Omachi H, Yamashita SI, Saishoji T, Nomura K, Sato H. Production of immunoreactive polymorphonuclear leucocyte elastase in human breast cancer cells: possible role of polymorphonuclear leucocyte elastase in the progression of human breast cancer. Br J Cancer 1994, 69:72-76. 10.1038/bjc.1994.11, 1968785, 8286213.
3. Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. Cancer Res 2003, 63:337-341.
4. Akizuki M, Fukutomi T, Takasugi M, Takahashi S, Sato T, Harao M, Mizumoto T, Yamashita J. Prognostic significance of immunoreactive neutrophil elastase in human breast cancer: long-term follow-up results in 313 patients. Neoplasia 2007, 9:260-264. 10.1593/neo.06808, 1838583, 17401466.
5. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV, Sallenave JM. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 2004, 172:4535-4544.
6. Tremblay GM, Vachon E, Larouche C, Bourbonnais Y. Inhibition of human neutrophil elastase-induced acute lung injury in hamsters by recombinant human pre-elafin (trappin-2). Chest 2002, 121:582-588. 10.1378/chest.121.2.582, 11834675.
7. Zhang M, Zou Z, Maass N, Sager R. Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level. Cancer Res 1995, 55:2537-2541.
8. Zani ML, Nobar SM, Lacour SA, Lemoine S, Boudier C, Bieth JG, Moreau T. Kinetics of the inhibition of neutrophil proteinases by recombinant elafin and pre-elafin (trappin-2) expressed in Pichia pastoris. Eur J Biochem 2004, 271:2370-2378. 10.1111/j.1432-1033.2004.04156.x, 15182352.
9. Motta JP, Magne L, Descamps D, Rolland C, Squarzoni-Dale C, Rousset P, Martin L, Cenac N, Balloy V, Huerre M, Frohlich LF, Jenne D, Wartelle J, Belaaouaj A, Mas E, Vinel JP, Alric L, Chignard M, Vergnolle N, Sallenave JM. Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 2011, 140:1272-1282. 10.1053/j.gastro.2010.12.050, 21199654.
10. Alkemade HA, Molhuizen HO, van Vlijmen-Willems IM, van Haelst UJ, Schalkwijk J. Differential expression of SKALP/Elafin in human epidermal tumors. Am J Pathol 1993, 143:1679-1687. 1887253, 8256855.
11. Alkemade HA, van Vlijmen-Willems IM, van Haelst UJ, van de Kerkhof PC, Schalkwijk J. Demonstration of skin-derived antileukoproteinase (SKALP) and its target enzyme human leukocyte elastase in squamous cell carcinoma. J Pathol 1994, 174:121-129. 10.1002/path.1711740208, 7965407.
12. Alkemade JA, Molhuizen HO, Ponec M, Kempenaar JA, Zeeuwen PL, de Jongh GJ, van Vlijmen-Willems IM, van Erp PE, van de Kerkhof PC, Schalkwijk J. SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J Cell Sci 1994, 107:2335-2342.
13. Yamamoto S, Egami H, Kurizaki T, Ohmachi H, Hayashi N, Okino T, Shibata Y, Schalkwijk J, Ogawa M. Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of the oesophagus. Br J Cancer 1997, 76:1081-1086. 10.1038/bjc.1997.511, 2228093, 9376270.
14. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
15. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
16. Liu Y, Chen JJ, Gao Q, Dalal S, Hong Y, Mansur CP, Band V, Androphy EJ. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol 1999, 73:7297-7307. 104255, 10438818.
17. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996, 56:4620-4624.
18. Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990, 50:6075-6086.
19. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000, 60:5359-5364.
20. Hunt KK, Deng J, Liu TJ, Wilson-Heiner M, Swisher SG, Clayman G, Hung MC. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 1997, 57:4722-4726.
21. Vorburger SA, Pataer A, Yoshida K, Liu Y, Lu X, Swisher SG, Hunt KK. The mitochondrial apoptosis-inducing factor plays a role in E2F-1-induced apoptosis in human colon cancer cells. Ann Surg Oncol 2003, 10:314-322. 10.1245/ASO.2003.05.021, 12679318.
22. Hornebeck W, Derouette JC, Brechemier D, Adnet JJ, Robert L. Elastogenesis and elastinolytic activity in human breast cancer. Biomedicine 1977, 26:48-52.
23. Sato T, Takahashi S, Mizumoto T, Harao M, Akizuki M, Takasugi M, Fukutomi T, Yamashita J. Neutrophil elastase and cancer. Surg Oncol 2006, 15:217-222. 10.1016/j.suronc.2007.01.003, 17320378.
24. Yokota T, Bui T, Liu Y, Yi M, Hunt KK, Keyomarsi K. Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Res 2007, 67:11272-11283. 10.1158/0008-5472.CAN-07-2322, 18056453.
25. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005, 7:R953-964. 10.1186/bcr1325, 1410752, 16280042.
26. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001, 21:6254-6269. 10.1128/MCB.21.18.6254-6269.2001, 87349, 11509668.
27. Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle 2003, 2:461-466.
28. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 2005, 280:15148-15157. 10.1074/jbc.M409789200, 15708847.
29. Caruso JA, Hunt KK, Keyomarsi K. The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. Cancer Res 2010, 70:7125-7136. 10.1158/0008-5472.CAN-10-1547, 2940941, 20823156.
30. Yu KS, Lee Y, Kim CM, Park EC, Choi J, Lim DS, Chung YH, Koh SS. The protease inhibitor, elafin, induces p53-dependent apoptosis in human melanoma cells. Int J Cancer 2009, 127:1308-1320.
31. Henriksen PA, Devitt A, Kotelevtsev Y, Sallenave JM. Gene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastase-mediated impairment of apoptotic cell recognition. FEBS Lett 2004, 574:80-84. 10.1016/j.febslet.2004.08.008, 15358543.
32. Sansregret L, Goulet B, Harada R, Wilson B, Leduy L, Bertoglio J, Nepveu A. The p110 isoform of the CDP/Cux transcription factor accelerates entry into S phase. Mol Cell Biol 2006, 26:2441-2455. 10.1128/MCB.26.6.2441-2455.2006, 1430290, 16508018.
33. Michl P, Ramjaun AR, Pardo OE, Warne PH, Wagner M, Poulsom R, D'Arrigo C, Ryder K, Menke A, Gress T, Downward J. CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell 2005, 7:521-532. 10.1016/j.ccr.2005.05.018, 15950902.
34. Goulet B, Markovic Y, Leduy L, Nepveu A. Proteolytic processing of cut homeobox 1 by neutrophil elastase in the MV4;11 myeloid leukemia cell line. Mol Cancer Res 2008, 6:644-653. 10.1158/1541-7786.MCR-07-0268, 18403643.
35. Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Liu S, Molldrem JJ. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anti-cancer adaptive immune response. Cancer Res 2012, 72:3153-3162. 10.1158/0008-5472.CAN-11-4135, 22564522.
36. Gregory AD, Hale P, Perlmutter DH, Houghton AM. Clathrin pit-mediated endocytosis of neutrophil elastase and cathepsin G by cancer cells. J Biol Chem 2012, 287:35341-35350. 10.1074/jbc.M112.385617, 22915586.